Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken-ichi Harada

Showing results (11-20 of 153) with videos related to

Pageof 16
Sort By:
Optics Letters|April 6, 2007
Four-wave parametric oscillation in sodium vapor by electromagnetically induced diffractionKen-ichi Harada, Minoru Ogata, Masaharu Mitsunaga
Environmental Toxicology|November 15, 2007
Phosphoprotein analysis for investigation of in vivo relationship between protein phosphatase inhibitory activities and acute hepatotoxicity of microcystin-LRMasahiko Tachi, Susumu Y Imanishi, Ken-Ichi Harada
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Anticancer Research|May 13, 2015
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell CarcinomaAkira Miyazaki, Hideaki Miyake, Ken-Ichi Harada, et al.
Journal of Chromatography. A|April 10, 2004
Comprehensive analysis system using liquid chromatography-mass spectrometry for the biosynthetic study of peptides produced by cyanobacteriaKen-ichi Harada, Tomoyo Nakano, Kiyonaga Fujii, et al.
Medical Oncology (Northwood, London, England)|February 21, 2015
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinibHideaki Miyake, Ken-ichi Harada, Akira Miyazaki, et al.
Medical Oncology (Northwood, London, England)|October 15, 2013
Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitorsMasafumi Kumano, Hideaki Miyake, Ken-ichi Harada, et al.
Current Urology|February 19, 2016
Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core BiopsyHiromoto Tei, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|May 6, 2014
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in JapanHideaki Miyake, Akira Miyazaki, Ken-Ichi Harada, et al.
BJU International|June 21, 2012
Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomyKen-ichi Harada, Hideaki Miyake, Yuji Kusuda, et al.
Pageof 16

Showing results (11-20 of 153) with videos related to

Sort By:
Pageof 16
Optics Letters|April 6, 2007
Four-wave parametric oscillation in sodium vapor by electromagnetically induced diffractionKen-ichi Harada, Minoru Ogata, Masaharu Mitsunaga
Environmental Toxicology|November 15, 2007
Phosphoprotein analysis for investigation of in vivo relationship between protein phosphatase inhibitory activities and acute hepatotoxicity of microcystin-LRMasahiko Tachi, Susumu Y Imanishi, Ken-Ichi Harada
Clinical Genitourinary Cancer|July 31, 2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in JapanHideaki Miyake, Ken-Ichi Harada, Seiichiro Ozono, et al.
Anticancer Research|May 13, 2015
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell CarcinomaAkira Miyazaki, Hideaki Miyake, Ken-Ichi Harada, et al.
Journal of Chromatography. A|April 10, 2004
Comprehensive analysis system using liquid chromatography-mass spectrometry for the biosynthetic study of peptides produced by cyanobacteriaKen-ichi Harada, Tomoyo Nakano, Kiyonaga Fujii, et al.
Medical Oncology (Northwood, London, England)|February 21, 2015
Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinibHideaki Miyake, Ken-ichi Harada, Akira Miyazaki, et al.
Medical Oncology (Northwood, London, England)|October 15, 2013
Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitorsMasafumi Kumano, Hideaki Miyake, Ken-ichi Harada, et al.
Current Urology|February 19, 2016
Detection of Significant Prostate Cancer According to Anatomical Areas of Sampling Cores Obtained with Transrectal Systematic 12-Core BiopsyHiromoto Tei, Hideaki Miyake, Ken-Ichi Harada, et al.
Medical Oncology (Northwood, London, England)|May 6, 2014
Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in JapanHideaki Miyake, Akira Miyazaki, Ken-Ichi Harada, et al.
BJU International|June 21, 2012
Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomyKen-ichi Harada, Hideaki Miyake, Yuji Kusuda, et al.
Pageof 16